Asilomar International Conference on Climate Intervention Technologies

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Allergy, Neoplasm, FDA, Research, Psoriasis, Kidney cancer, NSCLC, Scientific Reports, Carcinoma, Pulmonary fibrosis, Nivolumab, Asilomar International Conference on Climate Intervention Technologies, T helper cell, Preprint, Scleroderma, PTCL, Pembrolizumab, Head, 65th Infantry Regiment, BioRxiv, Cytokine, Time management, Ipilimumab, RCC, ITK, Society, ASH, Clinical trial, Science, Asthma, Cancer, Webcast, Lung cancer, Autoimmunity, Total, Conference call, Patient, Lymphoma, Communications satellite, Pharmaceutical industry, Vaccine, Cryptocurrency, T helper 17 cell, Corvus, Conference

BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • The paper highlights the potential of selective ITK inhibition for the treatment of cancers and helps to confirm preclinical and clinical results generated by Corvus.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the third quarter 2023 financial results.

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 12, 2023
HIV disease progression rates, Drug development, European Organisation for Research and Treatment of Cancer, AACR, Asilomar International Conference on Climate Intervention Technologies, Central nervous system, Cancer, EORTC, National Cancer Institute, Patient, American Association for Cancer Research, Therapy, NCI, Research, Molecular biology, AR, Prostate cancer, CNS, Conference, CBP, Pharmaceutical industry

Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.

Key Points: 
  • Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.
  • The AACR-NCI-EORTC Conference attracts researchers from around the world to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.
  • Today’s presentation is the second in a series of important meetings at which the Proteovant team is sharing research findings that show potential best- and first-in-class protein degraders.
  • “Although strategies targeting androgen receptor in the treatment of prostate cancer have shown benefits for patients, the reality is that cancer cells ultimately find ways to bypass these therapies, resulting in disease progression," said Zhihua Sui, Ph.D. Chief Scientific Officer, Proteovant Therapeutics.

SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 13, 2023
HIV disease progression rates, Drug development, European Organisation for Research and Treatment of Cancer, AACR, Asilomar International Conference on Climate Intervention Technologies, Central nervous system, Cancer, EORTC, National Cancer Institute, Patient, American Association for Cancer Research, Therapy, Doctor of Philosophy, NCI, Research, Molecular biology, AR, Prostate cancer, CNS, Conference, CBP, Pharmaceutical industry

SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, presented data showing that selectively degrading the epigenetic protein p300, with minimal impact on its paralog CBP, results in suppression of androgen receptor signaling and inhibition of tumor growth in a mouse model of androgen receptor (AR) positive prostate cancer. Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.

Key Points: 
  • Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.
  • The AACR-NCI-EORTC Conference attracts researchers from around the world to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.
  • "These data showcase a first-in-class opportunity for therapeutic intervention that suppresses AR signaling through an androgen-independent mechanism."
  • "We are excited about what our Proteovant team is doing to find novel approaches to treat metastatic castration-resistant prostate cancer," Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science.

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Retrieved on: 
Friday, September 22, 2023
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Interim, Lymphoma, Cutaneous T-cell lymphoma, KIR3DL2, MF, EORTC, Euronext Paris, Asilomar International Conference on Climate Intervention Technologies, IPH, Patient, Lymph, IPHA, Node, Saint Louis Hospital (Bangkok), Conference, ORR, Caregiver, Pharmaceutical industry, Cryptocurrency, Vaccine, CTCL

The data were previously presented at the 17th International Conference on Malignant Lymphoma , in Lugano (Switzerland), in June 2023.

Key Points: 
  • The data were previously presented at the 17th International Conference on Malignant Lymphoma , in Lugano (Switzerland), in June 2023.
  • Lymph Node assessment is an important component of staging and response assessment in CTCL (cutaneous T cell lymphomas).
  • “We are pleased to present the interim results of the Phase 2 TELLOMAK study based on updated guidelines at the EORTC Cutaneous Lymphoma Tumour Group Meeting.
  • The higher global ORR according to updated lymph node further supports the ongoing development of lacutamab in T cell lymphomas.

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Lymphoma, European Hematology Association, Information technology, Chief business officer, LD, Clinical trial, NHL, G&A, NK, MRD, AML, Asilomar International Conference on Climate Intervention Technologies, Patient, Investment, EHA, CPA, R, Research, Conference, Life insurance, Fine chemical, Pharmaceutical industry, Vaccine

As previously announced, Nkarta plans to present updated results from its ongoing clinical trial of NKX019 in the second half of 2023.

Key Points: 
  • As previously announced, Nkarta plans to present updated results from its ongoing clinical trial of NKX019 in the second half of 2023.
  • In July 2023, Nkarta announced the appointment of Alyssa Levin, CPA, CA, as Chief Financial and Business Officer.
  • Non-cash stock-based compensation expense included in R&D expense was $2.1 million for the second quarter of 2023.
  • Net loss was $33.3 million, or $0.68 per basic and diluted share, for the second quarter of 2023.

Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma

Retrieved on: 
Friday, June 16, 2023
Graft-versus-host disease, Center for Cell and Gene Therapy, GVHD, Epstein–Barr virus, Baylor College of Medicine, ICML, Lymphoma, Baylor University, Cancer, Allotransplantation, Cell, Infrastructure as code, Asilomar International Conference on Climate Intervention Technologies, Cytokine release syndrome, Patient, Risk, HL, Immune system, Therapy, Conference, Gene therapy, Safety, Bone marrow, Pharmaceutical industry, Vaccine

The results were presented by Tessa collaborators at the Baylor College of Medicine in an oral podium presentation at the 17th International Conference on Malignant Lymphoma (ICML) taking place at Lugano, Switzerland.

Key Points: 
  • The results were presented by Tessa collaborators at the Baylor College of Medicine in an oral podium presentation at the 17th International Conference on Malignant Lymphoma (ICML) taking place at Lugano, Switzerland.
  • TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • “Importantly, CD30.CAR EBVSTs elicited a clinical response in 14 of 18 patients with R/R Hodgkin lymphoma including seven complete responses.
  • “The data presented at ICML are very promising and further validate our “off-the-shelf” CD30.CAR EBVST allogeneic cell therapy platform in R/R Hodgkin lymphoma,” stated Ivan Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics.

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

Retrieved on: 
Thursday, June 15, 2023
Research and development, CD19, ICML, Lymphoma, Cancer, Cyclophosphamide, B-cell lymphoma, ASCO, CAR, Development, Asilomar International Conference on Climate Intervention Technologies, American Society of Clinical Oncology, Kite Pharma, Patient, Risk, Annual general meeting, Pivotal, Therapy, Society, Conference, Pharmaceutical industry

Earlier in June, data from the 12 patients, a subset of these 33 CAR T naïve patients, who received regimen being utilized in ongoing Phase 2 trials was presented at American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Earlier in June, data from the 12 patients, a subset of these 33 CAR T naïve patients, who received regimen being utilized in ongoing Phase 2 trials was presented at American Society of Clinical Oncology (ASCO) Annual Meeting.
  • “The design and execution of our Phase 1 ALPHA/ALPHA 2 trials enabled a systematic evaluation of potential Phase 2 treatment regimens.
  • The median time from enrollment to the start of therapy was three days and 100% of patients received product per specifications.
  • The dosing breakdown for the 33 patients included in this data set is as follows:
    12 patients treated with a single dose of ALLO-501/501A and FCA90 lymphodepletion (Phase 2 regimen; recap of the ASCO 2023 data presentation)

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Retrieved on: 
Thursday, June 15, 2023
University, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, CD20, European Hematology Association, University of Washington, Lymphoma, History, Associate, Translation, CAR, Waldenström, Asilomar International Conference on Climate Intervention Technologies, Cytokine release syndrome, Patient, Cancer, CR, Mustang, Conference, ORR, DSM-IV codes, Disease, Pharmaceutical industry, Vaccine

WORCESTER, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that final data from the follicular lymphoma (“FL”) cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response (“ORR”) and complete response (“CR”) rates and CAR T persistence in FL patients. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).

Key Points: 
  • The final FL cohort results from the Phase 1/2 clinical trial being conducted at Fred Hutch were presented by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutch and University of Washington, at the 17th International Conference on Malignant Lymphoma (“17-ICML”).
  • Median age was 63 years (range: 44 – 81), and median prior lines of treatment was 4 (range: 1 – 12).
  • One patient, previously treated with a CD19-targeted CAR T-cell therapy, achieved a CR and remains in remission after 18 months.
  • We look forward to reporting initial data from our multicenter Phase 1/2 clinical trial of MB-106 shortly.”
    For more information on the multicenter clinical trial, please visit www.clinicaltrials.gov using the identifier NCT05360238 for the multicenter trial.

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

Retrieved on: 
Friday, June 16, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Peripheral T-cell lymphoma not otherwise specified, Hematopoietic stem cell transplantation, Lymphoma, Cutaneous T-cell lymphoma, KIR3DL2, MF, Bone marrow, Euronext Paris, Asilomar International Conference on Climate Intervention Technologies, IPH, Patient, Division, Lymph, IPHA, Node, Mycosis fungoides, Conference, ORR, Caregiver, Pharmaceutical industry, CTCL

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated lymph node classification confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated lymph node classification confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody.
  • The data were presented at the 17th International Conference on Malignant Lymphoma, in Lugano, Switzerland.
  • Lymph Node assessment is an important component of staging and response assessment in CTCL (cutaneous T cell lymphomas).
  • We thank the investigators, clinical research coordinators, patients and caregivers involved in the ongoing TELLOMAK program.”

Government of Canada extends Chief Statistician of Canada's term

Retrieved on: 
Wednesday, June 14, 2023
Statistics Act, The Honourable, Organization, United Nations, Innovation, Science and Economic Development Canada, Culture, Chief Statistician of Canada, Statistics, Agriculture, COVID-19, International Statistical Institute, Economy, Organisation for Economic Co-operation and Development controversy, OECD, Government, Committee, Congress, Census, Official statistics, Publication, Asilomar International Conference on Climate Intervention Technologies, World Statistics Day, Economic development, United Nations Statistical Commission, Statistics Canada, Government of Canada, Policy, Conference, Social media, Nursing, Science

Mr. Arora was first appointed Chief Statistician of Canada in September 2016, with his term renewed in June 2018 for another five years.

Key Points: 
  • Mr. Arora was first appointed Chief Statistician of Canada in September 2016, with his term renewed in June 2018 for another five years.
  • Mr. Arora will continue in this role until the end of March 2024, to enable the Government of Canada to identify and appoint a new Chief Statistician of Canada and support a seamless transition.
  • – The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry
    "I am pleased to continue to serve as the Chief Statistician of Canada until March 2024, marking more than 35 years of public service.
  • The Statistics Act was amended in 2017 to give the Chief Statistician of Canada authority for decisions on statistical matters and to increase government transparency.